All News
A reminder by @anisha_dua
➡️15% #PMR patients get #GCA
➡️ up to 50% GCA patients get PMR
#RNL2023
Mar 18, 2023
GCA biopsy: When and How
Early is best, rec'd in first 2 weeks. Findings can be present at 8 weeks but be less prominent
@anisha_dua rec's unilateral imaging in most pts, especially w scalp tenderness on one side
>1 cm length
#RNL2023 @RheumNow https://t.co/HBHBGeFm6J
Mar 18, 2023
Highest pre-test probability for GCA is actually:
1) Limb claudication
2) Jaw claudication
#RNL2023 @RheumNow https://t.co/13tDXMhJKM
Mar 18, 2023
@anisha_dua shares her take home points for PMR. Check out her great review below! #RNL2023 @rheumnow https://t.co/PAqXaXcXAb
Mar 18, 2023
@anisha_dua Table on imaging in LVV
U/S: increase specificity for PMR, operator dependent
CTA: high detail, contrast + radiation
MRA: cost and limitations in CKD, metal
PET/CT: useful but not specific for vasculitis and very high cost
#RNL2023 @RheumNow https://t.co/aTdrlPfN9J
Mar 18, 2023
Long-Term Survival of Idiopathic Inflammatory Myopathies
A single center cohort study analyzed the outcome and survival of IIM patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
https://t.co/oEuTNiUANc https://t.co/1lXiStqoEz
Links:
Mar 18, 2023
Should be revisit role of #MTX in OA?
Possibly some benefit in metabolically active #osteoarthritis
#RNL2023 #methotrexate https://t.co/DIxIYQNulv
Mar 18, 2023
MTX as a treatment of OA, by Dr.Conaghan #RNL2023 @RheumNow
Systemic inflammation might also be a part of OA?! https://t.co/grxMKtRLhj
Mar 18, 2023
⚠️Only 12-43% of #PsA patients achieved remission or very low disease activity
From systematic review in RWE presented by @DrLauraCoates
#RNL2023
Mar 18, 2023
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
@Rheumnow https://t.co/hA7JDR7Zyh
Mar 18, 2023
I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL
Mar 18, 2023
Treat to target in PSA: What's difference in our outcome scores?
DAPSA: includes CRP
MDA: includes enthesitis, skin, function
Both metrics include Tender/Swollen jt counts, and pt pain/global
Presented by @DrLauraCoates at #RNL2023
@RheumNow https://t.co/7i5m70HGiz
Mar 18, 2023
Dr. Laura Coates presents - Is remission in PsA attainable?
systematic review: 12-43% achieved very low disease activity or remission
#RNL2023 @RheumNow https://t.co/flfpzc7B4p
Mar 18, 2023
Triamcinolone joint injection, Dr.Conaghan #RNL2023 @RheumNow
Extended half life steroids injections are better?!:
1- better for sugar control.
2-longer effect. https://t.co/4T8frPJOXG
Mar 18, 2023
#RNL2023 @RheumNow
@DrLauraCoates: patients & physicians do not agree on what is remission in PsA
Patients global scores: largely driven by pain and fatigue, not on joint counts
Remission in PsA allows for disease control on Rx- not just drug-free remission, often not sustained https://t.co/Hr2uuWDAfr
Mar 18, 2023
Higher Rehospitalization Rates in Younger SLE Patients
A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
https://t.co/17Lbcw8TdC https://t.co/L6CwRCd1aS
Links:
Mar 18, 2023
Can we prevent RA, Kevin Deane #RNL2023 @RheumNow. https://t.co/EtUEs3MyCN
Mar 18, 2023
Upto 30% risk of #RA within 5 yrs if anti-CCP positive
#RNL23 https://t.co/E5wun837ud
Mar 18, 2023
Conaghan: "Most promising study in OA" at #RNL2023
NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated?
Can there be sustained response.
Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪
@RheumNow https://t.co/eBMEPBG9wn
Mar 18, 2023
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/2Y5am2YEsQ
Mar 18, 2023